A performance The size of a matchstick could revolutionize HIV prevention regime After initial tests suggested the device could prevent people at risk of contracting the virus for up to a year, new research shown on Tuesday.
Developers unveiled their findings from a clinical trial at the 10th Annual Meeting of the International AIDS Society in Mexico City, developers said the device could eventually offer a new approach to HIV suppression.
It uses a molecule called MK-8591, which is approximately 10 times stronger than an HIV inhibitor than drugs currently on the market, and which has a very high barrier to resistance.
Mike Robertson, Director of Global Clinical Development for Virology at MSD, "Slowly releases the drug and keeps a very consistent level of medicine in your body.
Meanwhile, people at high risk of contracting HIV need to take a pill every day to ensure their protection.
In their annual report on the disease, the United Nations said this month that global AIDS deaths had fallen by a third since 2010, reaching about 770,000 in 2018.
But it has warned that the decline in rates of new infections is slowly increasing, and in some regions, including Eastern Europe and the Middle East, rates are rising dramatically.
Robertson said that the immigrant, or even a human pillar, with the same active spirit, could provide more opportunities for risk communities.
"People who are the most threatened are different populations – for example, people who have sex with people are still the group with the highest rate of new infections in the US and Europe," he said.
"But globally, the highest incidence rate is among young women in sub-Saharan Africa, and this is another group where most new infections occur."
Ancient AIDS Society president Poznańak said the immigrant would "bring another option for those who may have given pills and injectables in the future" to prevent infection.
This Tuesday also presented a new analysis revealing a recent clinical study on HIV safety and tolerance.
The phase 2 process was conducted in Kenya, Rwanda and the United States between health, low-risk, HIV-negative adults. Initial results showed that vaccines are well tolerated in humans.
A phase 3 process is currently in the works.
Roger Tatoud, Director of Global, "These are very promising times for HIV vaccine research, with multiple efficacy trials, new approaches to development and a growing feeling that we may be approaching an effective vaccine. HIV Vaccine Enterprise.